ASP4345

DRUG2 trials

Sponsors

Astellas Pharma Global Development, Inc.

Conditions

Schizophrenia

Phase 1

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

CompletedNCT02720263

Astellas Pharma Global Development, Inc.Schizophrenia

Start: 2016-03-28End: 2017-06-08Updated: 2024-10-31

Phase 2

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

CompletedNCT03557931

Astellas Pharma Global Development, Inc.Schizophrenia

Start: 2018-07-13End: 2019-10-21Updated: 2024-11-12

Related Papers

Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.

2021-01-014 citations

Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia

Neuropsychopharmacology2020-11-1719 citations